Hill-Rom Receives a Buy from Stifel Nicolaus

By Austin Angelo

In a report issued on July 28, Rick Wise from Stifel Nicolaus reiterated a Buy rating on Hill-Rom (NYSE: HRC), with a price target of $84. The company’s shares closed on Friday at $74.74.

According to TipRanks.com, Wise is a 5-star analyst with an average return of 12.6% and a 71.4% success rate. Wise covers the Healthcare sector, focusing on stocks such as Corindus Vascular Robotics, Trivascular Technologies, and Obalon Therapeutics Inc.

Currently, the analyst consensus on Hill-Rom is Strong Buy and the average price target is $87.25, representing a 16.7% upside.

In a report issued on July 28, Needham also reiterated a Buy rating on the stock with a $93 price target.

The company has a one year high of $84.65 and a one year low of $50.50. Currently, Hill-Rom has an average volume of 481.9K.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. Last month, Andreas Frank, the SVP Corp Develop & Strategy of HRC sold 10,660 shares for a total of $838,040.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Hill-Rom Holdings, Inc. is a medical technology company, which focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care, and Surgical Solutions.